|
Jun 2
|
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
|
|
May 28
|
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
|
|
May 24
|
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute
|
|
May 23
|
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
|
|
Mar 14
|
One Liquidia Insider Raised Their Stake In The Previous Year
|
|
Mar 12
|
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
|
|
Feb 24
|
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
|
|
Feb 21
|
US Growth Stocks With High Insider Ownership Seeing Up To 48% Revenue Growth
|
|
Oct 9
|
Liquidia Corp (LQDA) Q2 2024 Earnings Call Highlights: Navigating Challenges and Opportunities ...
|
|
Oct 8
|
Liquidia Technologies (LQDA) Surges 11.2%: Is This an Indication of Further Gains?
|
|
Oct 7
|
Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute
|
|
Oct 7
|
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
|
|
Oct 2
|
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
|
|
Sep 30
|
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
|
|
Aug 28
|
Liquidia to Present at Upcoming Investor Conferences
|
|
Aug 26
|
Jim Cramer Says Liquidia Corporation (LQDA) Has Been Going ‘Down, Down, Down’
|
|
Jul 19
|
High Insider Ownership Marks These US Growth Companies For July 2024
|
|
Jun 10
|
Liquidia Insiders Placed Bullish Bets Worth US$3.00m
|
|
May 15
|
Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
|
|
May 15
|
Q1 2024 Liquidia Corp Earnings Call
|